Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from Medical University of Vienna yields new data on breast cancer
October 2nd, 2008
" In Her2-postive metastatic breast carcinoma, first-line trastuzumab-based therapy is well established; many centres continue antibody treatment beyond disease progression. In this trial, we evaluated the efficacy and safety of gemcitabine and trastuzumab after earlier exposure to anthracyclines, docetaxel and/or vinorelbine, and trastuzumab," scientists in Vienna, Austria report. " Twenty-nine consecutive patients were included as eligible. Patients received gemcitabine at a dose of 1,250 mg/m(2) on day one and eight, every 21 days. Trastuzumab was administered in three-week cycles. Clinical benefit rate (CBR; CR + PR + SD >= 6 months) was defined as primary...
Source: Women's Health Weekly (2008-10-02)
|
